Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $69.70 | Total: $348.50 |
| 1 | 10 | $59.04 | Total: $590.40 |
| 1 | 25 | $50.02 | Total: $1,250.50 |
| 1 | 50 | $42.64 | Total: $2,132.00 |
| 1 | 100 | $36.90 | Total: $3,690.00 |
Overview
CVN424 is a selective and novel GPR6 Inverse agonist effective in models of Parkinson Disease.
Chemical Properties
| Molecular Formula | C24H29F2N5O3 |
| Molecular Weight | 473.52 |
| CAS Numbers | 2254706-21-1 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | CC(=O)N1CCc2nc(N3CCC(CC3)Oc3ccc(F)cc3F)c(N[C@@H]3CCOC3)nc2C1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Nicola L Brice, et al. Development of CVN424 A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease. J Pharmacol Exp Ther. 2021 Jun;377[3] 407-416.